May 20 (Reuters) - 2cureX AB 2CUREX.ST :
* 2CUREX'S CLINICAL PARTNER, UNIVERSITY HOSPITAL VEJLE,
PRESENTS
POSITIVE RESULTS OF THE INDITREAT®-GUIDED CLINICAL TRIAL IN
THIRD LINE METASTATIC COLORECTAL CANCER AT THE ASCO 2021 ANNUAL
MEETING
* PRIMARY ENDPOINT OF TRIAL WAS MET
* PRIMARY ENDPOINT WAS PROGRESSION FREE SURVIVAL (PFS) AFTER
8
WEEKS OF TREATMENT
Source text for Eikon: ID:nWkr7pGFqX
Further company coverage: 2CUREX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))